Providence's lead mRNA COVID-19 vaccine candidate, which is currently in Phase 2 clinical trials, has demonstrated it is generally safe and well-tolerated and that the dosed subjects have high neutralization titers against the original strain of SARS-CoV-2 in an S protein-typed pseudovirus assay.

The other two antibody test products, Finecare SARS-CoV-2 Antibody Test and Finecare SARS-CoV-2 IgM Test, which use fluorescence immunochromatographic assay, are yet to be approved by the NMPA, but are even faster-they can detect either IgM antibody or both IgM and IgG antibodies within 10 minutes.

A researcher uses a pipette to develop an assay to detect a specific gene of corn at a lab in the Syngenta Biotech Center in Beijing.